Global EditionASIA 中文雙語Fran?ais
Opinion
Home / Opinion / Opinion Line

Domestic COVID-19 drug raises hopes

China Daily | Updated: 2022-08-16 07:45
Share
Share - WeChat

The National Healthcare Security Administration has announced that all the medicines listed in the COVID-19 treatment plan can be paid for through the healthcare security fund.

On Aug 9, the National Health Commission said that Azvudine, a Chinese drug approved for treating COVID-19, was included in the COVID-19 treatment plan. This way, patients can get part of the cost paid for by the healthcare security fund.

A worker carries out sample testing in a medical company in Jiangsu province, on April 9, 2020. [Photo by Tang Dehong/for China Daily]

Society has long been expecting COVID-19 drugs to enter the market. China has long developed vaccines aimed at preventing the virus from infecting more people. The emerging drugs will further consolidate China's victory over the virus.

Azvudine, as the first domestically developed COVID-19 drug, has several advantages over foreign ones. It costs less than 300 yuan ($44.35) per bottle, which is largely affordable; it is an oral drug rather than injection, which makes it convenient to popularize it.

Besides, since Azvudine has long been used to fight AIDS and has recently been developed to fight COVID-19, its side-effects are known.

However, some believe that more clinical data is needed to prove its effectiveness. After all, Azvudine has not been tested yet for its effectiveness against COVID-19. That's possibly why the medicine has been "temporarily" included in the healthcare fund, creating room for a long-term decision to be taken after observation. In that way, the taxpayers' burden will not be that heavy.

More than two years into the COVID-19 pandemic, people are looking for an effective, cheap drug to counter it.

With the first domestically developed COVID-19 drug entering the market and getting included in the healthcare fund, there is more light at the end of the tunnel. Of course, one single drug is far from enough in fighting the pandemic, yet it highlights the spirit of doing scientific research for fighting the pandemic.

We look forward to more such drugs being developed to better serve the people in the fight against the pandemic.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 91精品国产乱码在线观看| 久久伊人色综合| 精品久久久久久无码国产| 国产精品66在线观看| 免费a级毛视频| 国产精品永久免费10000| 无遮挡a级毛片免费看| 午夜欧美精品久久久久久久| a拍拍男女免费看全片| 好大好湿好硬顶到了好爽视频 | 亚洲欧美日韩在线一区| 老师在办公室被躁在线观看| 国产理论在线观看| 99精品全国免费观看视频| 无码精品久久久天天影视| 亚洲人午夜射精精品日韩| 玩山村女娃的小屁股| 国产www视频| 国产在线资源站| 国内精品久久久久久99蜜桃| 中文字幕久久久| 日韩欧美卡一卡二卡新区| 亚洲欧洲校园自拍都市| 第一次处破女18分钟高清| 国产三级精品三级| 很黄很污的视频网站| 国产综合成人亚洲区| japanese性暴力| 成品人视频ww入口| 久久精品无码中文字幕| 欧美日韩不卡视频| 国产免费的野战视频| 制服丝袜怡红院| 天堂/在线中文在线资源官网 | 国产精品亚洲专区一区| cctv新闻频道在线直播| 成年性生交大片免费看| 久久国产精品免费看| 狼友av永久网站免费观看| 四虎成人精品无码永久在线| 成人爽爽激情在线观看|